Cue Biopharma's Stock Shoots Up After CUE-101 Shows Promise In Early-Stage Head & Neck Cancer Study

  • Cue Biopharma Inc CUE has announced interim clinical data from its ongoing Phase 1a/1b monotherapy study of CUE-101 as second-line treatment for patients with human papilloma virus-positive recurrent/metastatic head and neck squamous cell carcinoma (HPV+ R/M HNSCC).
  • Interim analysis highlights include:
    • Confirmed partial response (PR) in one patient and stable disease (SD) in five patients, providing early signs of potential single-agent activity of CUE-101.
    • Demonstrated evidence of both tumor-specific CD8+ T cell expansion and dose-dependent increases in NK cells in patients.
    • Observed immune cell infiltration and tumor cell necrosis in patient tumor biopsies after CUE-101 treatment.
    • Dose-proportional PK profile and comparable drug exposure levels in patients receiving repeated dosing cycles, consistent with a lack of drug-clearing anti-drug antibodies.
    • No maximum tolerated dose was observed in patients dosed with up to 8 mg/kg of CUE-101.
  • The company plans a potential selection of a recommended Phase 2 dose of CUE-101 by mid-2021 for further development as monotherapy in HPV+ R/M HNSCC.
  • It also intends to report initial Phase 1 results from the combination study of CUE-101 with pembrolizumab in the second half of 2021 and initiate a Phase 2 neoadjuvant study with CUE-101 in the second half of 2021.
  • Price Action: CUE is trading 30.6% higher at $14.71 during the market trading session on the last check Monday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsHealth CareSmall CapGeneralBriefscancerneck cancerPhase 1 Trial
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!